Then, we tuned the aggregated parameters using the biological constrains, described in Material and Methods, combined with the experimental values of breast cancer volumes and the proportion of CSCs derived from the percentage of Sca-1+ and CD44+/CD24− cells. The gene discussed is CD44; the disease is breast carcinoma.